CXCL13/CXCR5 Chemokine Axis Promotes CXCR5 + CD19 + B-Cell and Follicular/Effector CXCR5 + CD4 + T-Cell Responses in the Lungs Associated with Protection from Severe and Fatal COVID-19 Following Infection with Pathogenic SARS-CoV-2 Delta Variant

Résumé fourni par la source

ABSTRACT Chemokines play an important role in shaping lung innate and adaptive immunity to pulmonary infections and diseases. However, the role of CXC ligand 13 (CXCL13), a chemokine homeostatically produced by various lung cell types, in the protection from SARS-CoV-2 infection and disease remains controversial. Some studies reported that asymptomatic patients who survived severe COVID-19 had CXCL13-dominated mucosal immune responses in the lungs early during infection. In contrast, other studies reported that a high level of CXCL13 was associated with severity and mortality in COVID-19 patients. In this study, to determine the direct role of CXCL13 in SARS-CoV-2 infection and disease, we generated CXCL13 -/- K18-hACE2 mice, that are both transgenic for ACE2 and deficient in CXCL13 and compared their infection and COVID-19-like disease symptoms with those in wild-type K18-hACE2 transgenic mouse littermates following intranasal inoculation with the pathogenic SARS-CoV-2 delta variant (B.1.617.2). Compared to age- and gender-matched SARS-CoV-2 infected wild-type K18-hACE2 mice, SARS-CoV-2 infected CXCL13 -/- K18-hACE2 deficient mice exhibited ( i ) higher viral load in the lungs; ( ii ) severe COVID-19-like lung pathology; ( iii ) exacerbated weight loss; ( iv ) increased mortality. The apparent severe COVID-19-like symptoms in CXCL13 -/- K18-hACE2 deficient mice were associated with: ( i ) significantly lower frequencies of functional lung-resident C-X-C chemokine receptor 5 + (CXCR5) + CD19 + B cells, follicular CXCR5 + CD4 + helper T cells (Tfh cells), and IFN-ψ + TNF-α + GzmB + Ki67 + effector CD4 + Th 1 cells; and ( ii ) a significant reduction in the levels of SARS-CoV-2-Spike specific Th1 associated IgG 1 and IgG 2b antibody isotypes. These findings corroborate previous human reports suggesting a critical role of the CXCL13/CXCR5 chemokine axis in the protective B- and T-cell mucosal immunity to SARS-CoV-2 infection and disease, offering a potential new immunotherapeutic target for treatment.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.